{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:39:25Z","timestamp":1790775565512,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Education and Research, the German Center for Lung Research","award":["FKZ82DZL40502 and FKZ82DZLC15A2"],"award-info":[{"award-number":["FKZ82DZL40502 and FKZ82DZLC15A2"]}]},{"name":"Sterna Biologicals GmbH & Co. KG"},{"name":"Vectura"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12931-018-0751-x","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:21:49Z","timestamp":1522801309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-3014","authenticated-orcid":false,"given":"Timm","family":"Greulich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens M.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Neuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lueer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Schade-Brittinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Harnisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Garn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Homburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"751_CR1","doi-asserted-by":"crossref","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3).","DOI":"10.1183\/13993003.00214-2017"},{"key":"751_CR2","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa032158","volume":"350","author":"JC Hogg","year":"2004","unstructured":"Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645\u201353.","journal-title":"N Engl J Med"},{"key":"751_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000330667","volume":"83","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B, Mistry V, Reid C, Parker D, Dodson P, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83:36\u201344.","journal-title":"Respiration"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000221902","volume":"78","author":"M Bafadhel","year":"2009","unstructured":"Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, Dodson P, Pavord ID, Newbold P, Brightling CE. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78:256\u201362.","journal-title":"Respiration"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, investigators E. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697\u2013700.","journal-title":"Eur Respir J"},{"key":"751_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/thx.2004.032516","volume":"60","author":"CE Brightling","year":"2005","unstructured":"Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavord ID, Bradding P. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193\u20138.","journal-title":"Thorax"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1183\/09031936.00146306","volume":"29","author":"R Siva","year":"2007","unstructured":"Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906\u201313.","journal-title":"Eur Respir J"},{"key":"751_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI8204","volume":"104","author":"A Ray","year":"1999","unstructured":"Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest. 1999;104:985\u201393.","journal-title":"J Clin Invest"},{"key":"751_CR9","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.4049\/jimmunol.161.8.3817","volume":"161","author":"DH Zhang","year":"1998","unstructured":"Zhang DH, Yang L, Ray A. Differential responsiveness of the IL-5 and IL-4 genes to transcription factor GATA-3. J Immunol. 1998;161:3817\u201321.","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"751_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1590\/S0074-02761997000800009","volume":"92","author":"PS Foster","year":"1997","unstructured":"Foster PS, Hogan SP, Matthaei KI, Young IG. Interleukin-4 and interleukin-5 as targets for the inhibition of eosinophilic inflammation and allergic airways hyperreactivity. Mem Inst Oswaldo Cruz. 1997;92(Suppl 2):55\u201361.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"751_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0091-6749(95)70265-2","volume":"96","author":"S Sur","year":"1995","unstructured":"Sur S, Gleich GJ, Swanson MC, Bartemes KR, Broide DH. Eosinophilic inflammation is associated with elevation of interleukin-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol. 1995;96:661\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"751_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nri3349","volume":"13","author":"JA Walker","year":"2013","unstructured":"Walker JA, Barlow JL, AN MK. Innate lymphoid cells--how did we miss them? Nat Rev Immunol. 2013;13:75\u201387.","journal-title":"Nat Rev Immunol"},{"key":"751_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145\u20139.","journal-title":"Nat Rev Immunol"},{"key":"751_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nm.3300","volume":"19","author":"GG Brusselle","year":"2013","unstructured":"Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19:977\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"751_CR15","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.chest.2017.05.019","volume":"152","author":"EH Bel","year":"2017","unstructured":"Bel EH, Ten Brinke A. New anti-eosinophil drugs for asthma and COPD: targeting the trait! Chest. 2017;152(6):1276\u20131282.","journal-title":"Chest."},{"issue":"17","key":"751_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613\u20131629.","journal-title":"N Engl J Med"},{"key":"751_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s001090100272","volume":"79","author":"FS Santiago","year":"2001","unstructured":"Santiago FS, Khachigian LM. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J Mol Med (Berl). 2001;79:695\u2013706.","journal-title":"J Mol Med (Berl)"},{"key":"751_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(12)62166-7","volume":"381","author":"EA Cho","year":"2013","unstructured":"Cho EA, Moloney FJ, Cai H, Au-Yeung A, China C, Scolyer RA, Yosufi B, Raftery MJ, Deng JZ, Morton SW, et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). Lancet. 2013;381:1835\u201343.","journal-title":"Lancet"},{"key":"751_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jaci.2007.12.1175","volume":"121","author":"S Sel","year":"2008","unstructured":"Sel S, Wegmann M, Dicke T, Sel S, Henke W, Yildirim AO, Renz H, Garn H. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol. 2008;121:910\u2013916.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"751_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.taap.2013.06.020","volume":"272","author":"A Turowska","year":"2013","unstructured":"Turowska A, Librizzi D, Baumgartl N, Kuhlmann J, Dicke T, Merkel O, Homburg U, Hoffken H, Renz H, Garn H. Biodistribution of the GATA-3-specific DNAzyme hgd40 after inhalative exposure in mice, rats and dogs. Toxicol Appl Pharmacol. 2013;272:365\u201372.","journal-title":"Toxicol Appl Pharmacol"},{"key":"751_CR21","doi-asserted-by":"crossref","unstructured":"Krug N, Hohlfeld JM, Buhl R, Renz J, Garn H, Renz H. Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients. J Allergy Clin Immunol. 2017;140(2):625\u2013628.e5.","DOI":"10.1016\/j.jaci.2017.02.024"},{"key":"751_CR22","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","volume":"372","author":"N Krug","year":"2015","unstructured":"Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015;372:1987\u201395.","journal-title":"N Engl J Med"},{"key":"751_CR23","first-page":"39","volume":"1","author":"S Saha","year":"2006","unstructured":"Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:39\u201347.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"751_CR24","doi-asserted-by":"publisher","first-page":"2S11","DOI":"10.1016\/S0761-8425(07)78156-1","volume":"24","author":"V Brusasco","year":"2007","unstructured":"Brusasco V, Crapo R, Viegi G. Coming together: the ATS\/ERS consensus on clinical pulmonary function testing. Rev Mal Respir. 2007;24:2S11\u201312S14.","journal-title":"Rev Mal Respir"},{"key":"751_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cyto.2014.10.008","volume":"71","author":"F Pedersen","year":"2015","unstructured":"Pedersen F, Holz O, Lauer G, Quintini G, Kiwull-Schone H, Kirsten AM, Magnussen H, Rabe KF, Goldmann T, Watz H. Multi-analyte profiling of inflammatory mediators in COPD sputum--the effects of processing. Cytokine. 2015;71:401\u20134.","journal-title":"Cytokine"},{"key":"751_CR26","doi-asserted-by":"crossref","unstructured":"American Thoracic Society; European Respiratory Society. ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912\u2013930.","DOI":"10.1164\/rccm.200406-710ST"},{"key":"751_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648\u201354.","journal-title":"Eur Respir J"},{"issue":"Suppl B","key":"751_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","volume":"85","author":"PW Jones","year":"1991","unstructured":"Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med. 1991;85(Suppl B):25\u201331.","journal-title":"Respir Med"},{"key":"751_CR29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","volume":"356","author":"CE Brightling","year":"2000","unstructured":"Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356:1480\u20135.","journal-title":"Lancet"},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","volume":"47","author":"NC Barnes","year":"2016","unstructured":"Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47:1374\u201382.","journal-title":"Eur Respir J"},{"key":"751_CR31","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390\u20138.","journal-title":"Lancet Respir Med"},{"key":"751_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","volume":"2","author":"CE Brightling","year":"2014","unstructured":"Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2:891\u2013901.","journal-title":"Lancet Respir Med"},{"key":"751_CR33","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","volume":"385","author":"PG Woodruff","year":"2015","unstructured":"Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015;385:1789\u201398.","journal-title":"Lancet"},{"key":"751_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2015.10.004","volume":"110","author":"KE Wurst","year":"2016","unstructured":"Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome. Respir Med. 2016;110:1\u201311.","journal-title":"Respir Med"},{"key":"751_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.rmed.2015.12.010","volume":"111","author":"H Worth","year":"2016","unstructured":"Worth H, Buhl R, Criee CP, Kardos P, Mailander C, Vogelmeier C. The 'real-life' COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64\u201371.","journal-title":"Respir Med"},{"key":"751_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Flezar M, Hebert J, McGarvey L, Pizzichini E, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45:969\u201379.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-018-0751-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:29:09Z","timestamp":1693607349000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-018-0751-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/s12931-018-0751-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved for all centres by the ethics committee at the University of Marburg as leading ethics committee (AZ: 149\/13 A-ff, Jan 2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Greulich reports personal fees from Astra Zeneca, personal fees from Berlin-Chemie, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from CSL-Behring, grants and personal fees from Grifols, personal fees from GSK, personal fees from Novartis, outside the submitted work; and reports grants from German Center for Lung Research during the conduct of the study.Dr. Hohlfeld reports personal fees from Boehringer Ingelheim, personal fees from Merck & Co, Inc., personal fees from Novartis, grants from Novartis, grants from Almirall, grants from Takeda, grants from ALK, grants from Boehringer Ingelheim, grants from LETI, grants from GlaxoSmithKline, grants from Sanofi-Aventis, grants from Allergopharma, grants from Astra Zeneca AB, outside the submitted work; and grants from German Center for Lung Research during the conduct of the study.P. Neuser reports grants from German Center for Lung Research during the conduct of the study.Dr. L\u00fcer reports grants from German Center for Lung Research during the conduct of the study.Dr. Klemmer reports grants from German Center for Lung Research during the conduct of the study.C. Schade-Brittinger reports grants from German Center for Lung Research, during the conduct of the study.S. Harnisch reports grants from German Center for Lung Research during the conduct of the study.Dr. Garn reports personal fees from sterna biologicals GmbH & Co. KG, during the conduct of the study; and is shareholder of sterna biologicals GmbH & Co.KG. Additionally, he reports grants from DZL (German Center for Lung Research) and UGMLC (Universities Gie\u00dfen and Marburg Lung Center) during the conduct of the study.Dr. Renz reports grants from Institute of Laboratory Medicine, during the conduct of the study; In addition, Dr. Renz has a patent GATA-3 DNAzyme licensed.U. Homburg reports other (employee) from sterna biologicals GmbH & Co KG, outside the submitted work.J. Renz reports other (employee) from Sterna Biologicals GmbH & Co. KG, outside the submitted work.Dr. Kirsten reports other from Sterna Biologicals, during the conduct of the study; other from Astra Zeneca, other from Berlin Chemie, other from Boehringer Ingelheim, other from Novartis, other from Astra Zeneca, other from Boehringer Ingelheim, other from Roche, other from GSK, other from Novartis, other from Chiesi, other from Takeda, other from Bayer, other from Sterna biologicals, other from Johnson u. Johnson, other from Sanofi, outside the submitted work.Dr. Pedersen reports grants from German Center for Lung Research, during the conduct of the study.Dr. Mueller reports grants from Novartis, grants from Allmirall, grants from Takeda, grants from Boehringer Ingelheim, grants from ALK, grants from LETI, grants from Glaxo SmithKline, grants from Sanofi-Aventis, grants from Allergopharma, grants from Astra Zeneca AB, outside the submitted work; and from German Center for Lung Research, during the conduct of the study.Dr. Vogelmeier reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from CSL Behring, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, personal fees from Menarini, personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Teva, personal fees from Cipla, outside the submitted work.Dr. Watz reports grants from German Center for Lung Research, during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"55"}}